newsfilter
← Latest News
PR Newswire·

AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3 LUNA study, which evaluated atogepant, a calcitonin gene-related...